Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05083806
Other study ID # 21-238_1-B
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 17, 2022
Est. completion date December 1, 2022

Study information

Verified date June 2022
Source University of Erlangen-Nürnberg Medical School
Contact Alexandra L. Wagner, MD
Phone +49913185
Email alexandra.l.wagner@uk-erlangen.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In patients with Pompe disease (PD) a progressive abnormal lysosomal glycogen storage in muscle tissue leads to impaired muscle function and to degeneration of muscle fibers. Children and adults with PD present with limb-girdle muscular weakness, diaphragm weakness and impaired breathing ability. Further, patients with classic infantile PD suffer from hypertrophic cardiomyopathy. To date, the muscle pathology and the extent of the disease can be assessed using invasive techniques (e.g., muscle biopsies) or imaging (e.g., MRI). These techniques are time consuming, and especially in young patients, require anesthesia, which increases the acute risk of respiratory failure. Multispectral optoacoustic tomography (MSOT) allows the detection of specific endogenous chromophores like collagen, myoglobin or hemoglobin by using a non-invasive approach comparable to conventional ultrasound. Instead of sound waves, MSOT illuminates tissue with near-infrared light of transient energy, which is absorbed and results in thermo-elastic expansion of certain molecules. This expansion generates ultrasound waves that are detected by the same device. Multispectral illumination and unmixing then allows the precise localisation and quantification of muscle-specific subcellular structures. MSOT has already been demonstrated the potential to visualize the muscular structure and the clinical extent of muscular disease in patients with Duchenne muscle dystrophy and differentiates those patients from healthy volunteers. The aim of the study is to establish glycogen as a novel PD-specific imaging target using MSOT-imaging. It intends to identify a PD-specific muscle pathology-signature by quantification of already established targets (collagen, myoglobin, hemoglobin, glycogen if applicable). This signature will aid in differentiating PD from other muscular pathologies and healthy volunteers and will ultimately serve as a potential non-invasive monitoring biomarker.


Description:

Pompe disease (PD) is a rare, autosomal-recessive disorder caused by deficiency of the lysosomal acid alpha-glucosidase enzyme (GAA), leading to generalized build-up of glycogen, especially in the heart, muscle, liver and nervous system. Among the glycogen storage diseases, PD is the only one with a defect in lysosomal metabolism. PD is considered as a progressive disease with variation by age of onset, severity of organ involvement and degree of myopathy. This great phenotypic variability has led to the creation of types based on the age of onset and degree of organ involvement. They all have in common, that symptoms of affected patients are expected to worsen over time if left untreated. The classification is generally based on the age of onset as infantile (infantile onset Pompe disease, IOPD) when it presents during the first 12 months of life and late-onset (LOPD) when first symptoms appear after 12 months of age. If cardiomyopathy is present, IODP is generally referred to as classic Pompe disease (however there may be variably classification in the literature with the infantile or childhood forms). Clinically, infants with classic PD present during the first few months of life with rapidly progressive disease characterized by prominent hypertrophic cardiomyopathy, hepatomegaly, hypotonia, generalized muscle weakness, macroglossia, feeding difficulties and respiratory insufficiency. Mortality rate is high by one year of age if untreated. Patients with non-classic PD will usually present within the first year of life with motor developmental delay and weakness, but without clinically relevant cardiac involvement. The rate of clinical progression is slower in these children and without treatment, death will usually occur in childhood as a result of respiratory insufficiency. LODP include childhood and adult-onset PD. These patients generally present with slowly progressive limb girdle type weakness and respiratory insufficiency without significant cardiomyopathy. The diagnosis of PD is usually established by the typical clinical presentation, followed by confirmation of GAA deficiency in dried blood spots, e.g. through new-born screening. Further (confirmatory) methods include GAA activity measurement in lymphocytes, muscle or skin fibroblasts, as well as GAA mutation testing. All of them are invasive techniques. Early identification is important as it will likely significantly improve the outcome for all patients with PD as treatment can be initiated earlier. Treating the underlying cause of PD involves the replacement of the missing enzyme GAA via enzyme replacement therapy (ERT) with alglucosidase alfa (recombinant human GAA, rhGAA). Currently, this is the only specific treatment approved for PD. In classical IOPD, treatment significantly lengthens survival and improves motor development and respiratory and cardiac function. The sooner ERT begins, the better are the results. With ERT being one very important aspect of care, patients will also need a multidisciplinary approach to ensure that all aspects of the disease are addressed.Regardless of age of onset and severity, all patients with PD should be monitored prospectively. However, there is lack of standardization across centers. A variety of clinical evaluations and tests are currently used for monitoring Pompe's disease, which may include laboratory tests including CK, AST, ALT, and LDH, cardiologic tests including electrocardiogram and echocardiogram and respiratory tests including sleep studies and breathing tests to measure lung capacity. To quantify muscle involvement electromyography is an option as well as clinical tests including 6 minutes walking test or timed to up and go test. Muscle MRI of affected patients often show fatty degeneration of muscles. One study showed that muscle MRI correlates with muscle function in patients with adult-onset Pompe disease. Another study suggested that muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy. For small children, however, there is always a need for sedation for MRI's, limiting its use. Therefore, ultrasound is another option to examine children's muscles. At the moment there are no prospective biomarkers available to detect muscle degeneration at an early age and/or to follow up disease progression or ERT-treated patients. Within the last years our multidisciplinary research team (Medical Department 1, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen) published a novel non-invasive imaging modality to be able to detect subcellular tissue composition in vivo. Multi-spectral optoacoustic tomography (MSOT), an imaging technology comparable to ultrasound, allows quantitative imaging in patients of all ages (including the non-sedated child).


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 1, 2022
Est. primary completion date September 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Pompe disease: - Confirmed diagnosis of Pompe disease - From 18 years of Age - Independent from current therapy Muscular dystrophy: - Genetically confirmed diagnosis - From 18 years of Age - Independent from current therapy Health volunteer: - From 18 years of Age, matched (age, gender) to PD collective Exclusion Criteria: Pompe disease: - Pregnancy - Tattoo on skin to be examined Muscular dystrophy: - Pregnancy - Tattoo on skin to be examined Health volunteer: - Anamnestic of other signs of myopathy or liver disease - Pregnancy - Tattoo on skin to be examined

Study Design


Intervention

Device:
Multispectral Optoacoustic Tomography
Non-invasive optoacoustic imaging of muscular structure

Locations

Country Name City State
Germany University Hospital Erlangen Erlangen Bavaria

Sponsors (1)

Lead Sponsor Collaborator
University of Erlangen-Nürnberg Medical School

Country where clinical trial is conducted

Germany, 

References & Publications (5)

Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT; AANEM Consensus Committee on Late-onset Pompe Disease. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012 Mar;45(3):319-33. doi: 10.1002/mus.22329. Epub 2011 Dec 15. Review. — View Citation

HERS HG. alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease). Biochem J. 1963 Jan;86:11-6. — View Citation

Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Crowley JF, Downs S, Howell RR, Kravitz RM, Mackey J, Marsden D, Martins AM, Millington DS, Nicolino M, O'Grady G, Patterson MC, Rapoport DM, Slonim A, Spencer CT, Tifft CJ, Watson MS. Pompe disease diagnosis and management guideline. Genet Med. 2006 May;8(5):267-88. Erratum in: Genet Med. 2006 Jun;8(6):382. ACMG Work Group on Management of Pompe Disease [removed]; Case, Laura [corrected to Case, Laura E]. — View Citation

Knieling F, Neufert C, Hartmann A, Claussen J, Urich A, Egger C, Vetter M, Fischer S, Pfeifer L, Hagel A, Kielisch C, Görtz RS, Wildner D, Engel M, Röther J, Uter W, Siebler J, Atreya R, Rascher W, Strobel D, Neurath MF, Waldner MJ. Multispectral Optoacoustic Tomography for Assessment of Crohn's Disease Activity. N Engl J Med. 2017 Mar 30;376(13):1292-1294. doi: 10.1056/NEJMc1612455. — View Citation

Regensburger AP, Fonteyne LM, Jüngert J, Wagner AL, Gerhalter T, Nagel AM, Heiss R, Flenkenthaler F, Qurashi M, Neurath MF, Klymiuk N, Kemter E, Fröhlich T, Uder M, Woelfle J, Rascher W, Trollmann R, Wolf E, Waldner MJ, Knieling F. Detection of collagens by multispectral optoacoustic tomography as an imaging biomarker for Duchenne muscular dystrophy. Nat Med. 2019 Dec;25(12):1905-1915. doi: 10.1038/s41591-019-0669-y. Epub 2019 Dec 2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Optoacoustic Absorption Spectrum of Muscle and liver in PD Difference in optoacoustic spectrum in patients compared to healthy volunteers 60 minutes for MSOT, 1 Visit
Secondary Quantitative glycogen signal (in arbitrary units) Difference of quantitative glycogen signal in Pompe disease patients compared to muscular dystrophy and healthy control 60 minutes for MSOT, 1 Visit
Secondary Quantitative lipid signal (in arbitrary units) Difference of quantitative lipid signal in Pompe disease patients compared to muscular dystrophy and healthy control 60 minutes for MSOT, 1 Visit
Secondary Quantitative collagen signal (in arbitrary units) Difference of collagen lipid signal in Pompe disease patients compared to muscular dystrophy and healthy control 60 minutes for MSOT, 1 Visit
Secondary Quantitative hemo/myoglobin signal (in arbitrary units) Difference of hemo/myoglobin lipid signal in Pompe disease patients compared to muscular dystrophy and healthy control 60 minutes for MSOT, 1 Visit
Secondary Muscle oxygenation (in %) Difference of muscle oxygenation in Pompe disease patients compared to muscular dystrophy and healthy control 60 minutes for MSOT, 1 Visit
Secondary Heckmatt scale Difference of Heckmatt scale in Pompe disease patients compared to muscular dystrophy and healthy control 30 minutes for B-mode-ultrasound, 1 Visit
Secondary Echogenitiy Difference of Echogenitiy in Pompe disease patients compared to muscular dystrophy and healthy control 30 minutes for B-mode-ultrasound, 1 Visit
Secondary Gray Scale Level Difference of Gray Scale Level in Pompe disease patients compared to muscular dystrophy and healthy control 30 minutes for B-mode-ultrasound, 1 Visit
Secondary Ultrasound Guided Attenuation Parameter (UGAP) of liver Difference of UGAP in Pompe disease patients compared to muscular dystrophy and healthy control 30 minutes for B-mode-ultrasound, 1 Visit
Secondary R-PaAt scale Difference of R-PaAt scale in Pompe disease patients compared to muscular dystrophy and healthy control 10 minutes, 1 Visit
Secondary Revised Upper Limb Module (RULM) Correlation of glycogen detected by MSOT with clinical scores 1 hour for total muscle testing, 1 Visit
Secondary MRC Muscle Strength Grades Correlation of glycogen detected by MSOT with clinical scores 1 hour for total muscle testing, 1 Visit
Secondary 6-minute-walk-test Correlation of glycogen detected by MSOT with clinical scores 1 hour for total muscle testing, 1 Visit
Secondary Stand-up and go test Correlation of glycogen detected by MSOT with clinical scores 1 hour for total muscle testing, 1 Visit
Secondary Quick motor function test Correlation of glycogen detected by MSOT with clinical scores 1 hour for total muscle testing, 1 Visit
Secondary Respiratory function test (FEV1, FVC) Correlation of glycogen detected by MSOT with respiratory function test 20 minutes, 1 Visit
Secondary Functional. magnetic resonance imaging of lung (Ventilation defect, perfusion defect, combined defects) Correlation of glycogen detected by MSOT with functional magnetic resonance imaging parameters 1 hour for total MR Imaging, 1 Visit
Secondary Magnetic resonance imaging of biceps muscle Correlation of glycogen detected by MSOT with magnetic resonance imaging parameters 1 hour for total MR Imaging, 1 Visit
See also
  Status Clinical Trial Phase
Completed NCT01942590 - Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy Phase 1/Phase 2
Not yet recruiting NCT01409486 - Screening for Early Detection and Prevention of Pompe Disease in Israel Using Tandem Mass Spectrometry N/A
Completed NCT00976352 - Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease Phase 1/Phase 2
Recruiting NCT01665326 - Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
Completed NCT01758354 - Newborn Screening Assay of Pompe's Disease N/A
Recruiting NCT00231400 - Pompe Disease Registry Protocol
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT04476550 - Clinical Specimen Collection From Pompe Disease Patients
Completed NCT01380743 - Drug-drug Interaction Study Phase 2
Recruiting NCT05734521 - Avalglucosidase Alfa Pregnancy Study
Completed NCT02742298 - Pompe Disease QMUS and EIM N/A
Terminated NCT02185651 - A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction Phase 1
Completed NCT02654886 - Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease. N/A
Completed NCT02405598 - Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease Phase 4
Completed NCT00701129 - An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease Phase 4
Completed NCT01451879 - Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies N/A
Completed NCT02240407 - Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease Phase 1
Completed NCT05073783 - A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting
Active, not recruiting NCT04093349 - A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE) Phase 1/Phase 2
Completed NCT02363153 - Diet and Exercise in Pompe Disease N/A